Please login to the form below

Not currently logged in


This page shows the latest Iressa news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets EU nod for Tagrisso rival Vizimpro

Pfizer gets EU nod for Tagrisso rival Vizimpro

Undeterred, Pfizer ran a third trial called ARCHER 1050 that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib), although ... Now, with approval on both sides of the

Latest news

More from news
Approximately 6 fully matching, plus 70 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    2016 saw GlaxoSmithKline (GSK) slash the price of its hepatitis drug Viread by two-thirds, and AstraZeneca halved the price of cancer drug Iressa, leading to a 16% decline in sales.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients with the EGFR mutation. ... Another development is AZD9291 – a drug which addresses the T790M mutation, which is a key resistance mechanism to

  • Payer focus in the personalised world of oncology and orphan diseases Payer focus in the personalised world of oncology and orphan diseases

    more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

  • Market access opportunities in China Market access opportunities in China

    In part as a result of these efforts, both Tarceva and Iressa have been appraised in the Guideline for Diagnosis and Treatment of Primary Lung Cancer published by the Ministry of

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....